Clinical Trial Update: Omecamtiv Mecarbil Post-trial Access Study [Phase 3]

View source ↗

Summary

Post-trial access study for omecamtiv mercabil (Omecamtiv Mecarbil) in chronic heart failure with reduced ejection fraction was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• omecamtiv mecarbil (omecamtiv mecarbil)

Snippet

Sponsor: Cytokinetics | Conditions: Chronic Heart Failure With Reduced Ejection Fraction | Phase 3 | Status: WITHDRAWN